LOUISVILLE, Kentucky, August 15, 2026, 16:42 EDT
- Humana shares gained 1.1% last week, closing Friday at $389.05.
- About 600,000 Medicare Advantage members face plan exits for 2027.
- Humana aims to retain 40% of those members in other products.
Humana Inc. NYSE:HUM rose last week as investors weighed a sharp Medicare Advantage reset against its 2028 margin target. The shares closed Friday at $389.05, up 1.1% over five sessions. U.S. markets are closed for the weekend.
The more useful number sits beneath the headline. Plan exits affecting about 600,000 members equal 9.3% of Humana’s June individual Medicare Advantage base. Yet the company expects to retain 40% through alternative offerings, according to a report published Saturday. That implies potential net attrition near 360,000, or 5.6% of the current base.
Those are preliminary calculations, not company enrollment guidance. Actual January membership will depend on plan availability, customer switching and fall enrollment.
| Security | Aug. 7 close | Aug. 14 close | Weekly change |
|---|---|---|---|
| Humana | $385.00 | $389.05 | +1.1% |
| UnitedHealth | $407.08 | $401.73 | -1.3% |
| CVS Health | $95.70 | $97.16 | +1.5% |
| Elevance Health | $394.20 | $400.32 | +1.6% |
| Health Care Select Sector SPDR | $165.68 | $167.37 | +1.0% |
The stock roughly matched the Health Care Select Sector SPDR Fund (NYSEARCA:XLV). UnitedHealth Group Inc. NYSE:UNH fell 1.3%. CVS Health Corp. NYSE:CVS and Elevance Health Inc. NYSE:ELV each gained about 1.5%.
Humana’s latest reported quarter showed strong growth with tighter medical economics. Second-quarter revenue rose 26.2% to $40.87 billion. Adjusted earnings increased 21.4% to $7.61 a share.
| Operating measure | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $40.87 billion | $32.39 billion | +26.2% |
| Adjusted EPS | $7.61 | $6.27 | +21.4% |
| Insurance benefit ratio | 91.2% | 89.9% | +130 bps |
| Adjusted operating cost ratio | 9.7% | 10.9% | -120 bps |
| CenterWell revenue | $6.79 billion | $5.54 billion | +22.6% |
The benefit ratio rose 130 basis points from a year earlier. New members typically carry higher initial medical costs, Humana said. A 120-basis-point drop in adjusted operating expenses partly offset that pressure.
This creates the central investor trade-off. Humana expects roughly 25% individual Medicare Advantage growth in 2026. Its 2027 bids now appear designed to exchange some volume for stronger unit margins.
| Medicare Advantage reset | Members | Share of June base |
|---|---|---|
| June 30 individual MA base | 6.454 million | 100.0% |
| Members in affected 2027 plans | About 600,000 | 9.3% |
| Targeted retention in other plans | About 240,000 | 3.7% |
| Potential net attrition | About 360,000 | 5.6% |
Management expects the 2027 bid approach to advance a sustainable pretax margin of at least 3% in 2028. It will update investors on that framework on December 10.
Chief Executive Jim Rechtin said the first half went “right where we said we’d be.” He linked better clinical care and efficiency to stronger earnings and customer outcomes. The company still forecasts at least $9.00 of adjusted EPS for 2026.
CenterWell offers a second lever. Its primary-care network served about 622,000 patients in June, up 27% from year-end. Humana operated 398 centers, 19% more than a year earlier.
| Research firm | Latest cited action | Rating | Target | Implied move from $389.05 |
|---|---|---|---|---|
| BofA Securities | July 29 upgrade | Buy | $500 | +28.5% |
| Wells Fargo | July 13 upgrade | Overweight | $502 | +29.0% |
| Truist Securities | July 14 maintained | Hold | $415 | +6.7% |
| TD Cowen | July 14 maintained | Hold | $350 | -10.0% |
The recommendations remain split. Bullish targets assume repricing and Star-ratings recovery lift margins. Hold ratings leave less room for execution errors after the stock’s steep rebound from its 52-week low.
In the week ahead, investors will look for more detail on affected counties and retention. The next near-term test is whether the shares hold Friday’s gain while peers disclose their own 2027 plan exits.
Risks: Medical costs may run above Humana’s high-single-digit assumption. Lower retention could deepen the revenue hit. Weak Star ratings, regulatory changes or slower CenterWell gains could also delay the 2028 margin goal.
Related articles: NYSE:HUM
